Chang Hung Chen

Title: Chang Hung Chen: Innovator in Fusion Protein Technology

Introduction

Chang Hung Chen is a notable inventor based in Germantown, Maryland, who has made significant contributions to the field of biotechnology. His work primarily focuses on the development of fusion proteins that have potential applications in cancer treatment. With one patent to his name, Chen is recognized for his innovative approach to addressing complex medical challenges.

Latest Patents

Chang Hung Chen's most recent patent is titled "Fusion constructs and methods of using thereof." This patent describes a fusion protein that comprises a first component, which is an antibody or a fragment or variant thereof, and a second component that includes a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody, which is known for its role in cancer immunotherapy. The patent also details how the antibody can bind to tumor antigens, such as MUC16 or MUC1 antigens, and includes a TGF-β trap as a cytokine trap. Additionally, the patent covers a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, and a composition that includes the fusion protein. The methods described in the patent highlight the potential use of this composition in cancer treatment.

Career Highlights

Chang Hung Chen is currently associated with Precigen, Inc., a company that focuses on advancing transformative therapies. His work at Precigen involves the development of innovative biopharmaceuticals that aim to improve patient outcomes in oncology. Chen's expertise in fusion protein technology positions him as a key player in the biotechnology sector.

Collaborations

Chang Hung Chen collaborates with notable colleagues, including Helen Sabzevari and Simon Metenou, who contribute to the advancement of research and development in their respective fields. Their combined efforts enhance the potential for groundbreaking discoveries in cancer treatment.

Conclusion

Chang Hung Chen's contributions to the field of fusion protein technology exemplify the innovative spirit of modern biotechnology. His patent on fusion constructs showcases the potential for new therapeutic approaches in cancer treatment. Through his work at Precigen, Inc., Chen continues to push the boundaries of scientific research and development.